Benefit-risk perception of natalizumab therapy in neurologists and a large cohort of multiple sclerosis patients

Christoph Heesen^*, Ingo Kleiter, Sven G. Meuth, Julia Krämer, Jürgen Kasper, Sascha Köpke, Wolfgang Gaissmaier

^*Korrespondierende/r Autor/-in für diese Arbeit